Metabolic syndrome in type 1 diabetes

International Journal of Diabetes Mellitus

Volumn 2, Issue 1, 2010, Pages 38-42

  Ghosh, Sujoy ^a   Collier, Andrew ^a   Hair, Mario ^b   Malik, Iqbal ^a   Elhadd, Tarik ^a  

^a AYR HOSPITAL   (United Kingdom)

^b UNIVERSITY OF THE WEST OF SCOTLAND   (United Kingdom)

Author keywords

Dyslipidaemia; Hypertension; Macro vascular complications; Medication; Metabolic syndrome; Micro vascular complications; Obesity; Type 1 diabetes

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TRIACYLGLYCEROL; UREA;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD PRESSURE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRIORITY JOURNAL; SEX DIFFERENCE; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; UREA BLOOD LEVEL;

EID: 77749332003     PISSN: 18775934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijdm.2009.10.005     Document Type: Article

References (40)

1. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome; 2003. [accessed 10.10.08].
2. Executive Summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
3. Alberti K.G., Zimmet P., and Shaw J. The metabolic syndrome: a new worldwide definition. Lancet 366 (2005) 1778
4. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Geneva (Switzerland): Department of Noncommunicable Disease Surveillance; 1999.
5. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation 25 112 (2005) 2735-2752
6. Isomaa B., Almgren P., Tuomi T., Forsén B., Lahti K., Nissen M., et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diab Care 24 (2001) 683-689
7. Lakka H.-M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
8. Bruno G., Merletti F., Biggeri A., Bargero G., Ferrero S., Runzo C., et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato Study. Diab Care 27 11 (2004) 2689-2694
9. Bonora E., Targher G., Formentini G., Calcaterra F., Lombardi S., Marini F., et al. The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications Study. Diab Med (2003) 52-58
10. Kilpatrick E.S., Rigby A.S., and Atkin S.L. Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: "double diabetes" in the Diabetes Control and Complications Trial. Diab Care 30 3 (2007) 707-712
11. Teupe B., and Bergis K. Epidemiological evidence for "double diabetes". Lancet 337 (1991) 361-362
12. Orchard T.J., Chang Y.F., Ferrell R.E., Petro N., and Ellis D.E. Nephropathy in type 1 diabetes: a manifestation of insulin resistance and multiple genetic susceptibilities?. Kidney Int 62 (2002) 963-970
13. Orchard T.J., Olson J.C., Erbey J.R., Williams K., Forrest K.Y.Z., Kinder L.S., et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications study. Diab Care 26 (2003) 1374-1379
14. Despres J.P., Lamarche B., Mauriege P., Cantin B., Dagenais G.R., Morrjani S., et al. Hyperinsulinaemia as an independent risk factor for ischaemic heart disease. N Engl J Med 334 (1996) 952-957
15. Bondonna R.C. The syndrome of insulin resistance and its links to atherosclerosis (2003), John Wiley and Sons
16. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. Geneva: World Health Org., Department of Noncommunicable Disease Surveillance; 1999, p. 31-3.
17. Thorn L.M., Forsblom C., Fagerudd J., Thomas M.C., Pettersson-Fernholm K., Saraheimo M., et al. Metabolic syndrome in type 1 diabetes. Association with diabetic nephropathy and glycemic control. Diab Care 28 8 (2005) 2019-2024
18. Saraheimo M., Teppo A.-M., Forsblom C., Fagerudd J., Groop P.-H., and FinnDiane Study Group. Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia 46 (2003) 1402-1407
19. Pambianco G., Costacou T., and Orchard T.J. The prediction of major outcomes of type 1 diabetes a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diab Care 30 5 (2007) 1248-1254
20. Saely C.H., Koch L., Schmid F., Marte T., Aczel S., Langer P., et al. Treatment Panel III 2001 but not International Diabetes Federation 2005 criteria of the metabolic syndrome predict clinical cardiovascular events in subjects who underwent coronary angiography. Diab Care 29 4 (2006) 901-907
21. Yip J., Mattock M.B., Morocutti A., Sethi M., Trevisan R., and Viberti G. Insulin resistance in insulin-dependent diabetic patients with microalbuminuria. Lancet 342 8876 (1993) 883-887
22. Deckert T., Feldt-Rasmussen B., Borch-Johnsen K., Jensen T., and Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia 32 (1989) 219-226
23. The Scottish Health Survey. In: Cardiovascular disease, vol. 1. Scotland: Information and Statistics; 2003. [accessed 10.10.08].
24. Sobal J. Globalization and the epidemiology of obesity. Int J Epidemiol 30 (2001) 1136-1137
25. Sobal J. Social and cultural influences on obesity. In: Bjorntorp P. (Ed). International textbook of obesity (2001), John Wiley and Sons, New York 305-322
26. Pambianco G., Costacou T., and Orchard T.J. The prediction of major outcomes of type 1 diabetes: a 12-year prospective evaluation of three separate definitions of the metabolic syndrome and their components and estimated glucose disposal rate: the Pittsburgh Epidemiology of Diabetes Complications Study experience. Diab Care 30 5 (2007) 1248-1254
27. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 14 (1993) 977-986
28. The Diabetes Control and Complications Trial Research Group. Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 75 14 (1995) 894-903
29. Purnell J.Q., Hokanson J.E., Marcovina S.M., Steffes M.W., Cleary P.A., and Brunzell J.D. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. JAMA 280 2 (1998) 140-146
30. Nathan D.M., Cleary P.A., Backlund J.Y., Genuth S.M., Lachin J.M., Orchard T.J., et al., Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 25 (2005) 2643-2653
31. Bonadonna R.C., Cucinotta D., Fedele D., Riccardi G., and Tiengo A. Metascreen Writing Committee. The metabolic syndrome is a risk indicator of microvascular and macrovascular complications in diabetes: results from Metascreen, a multicenter diabetes clinic-based survey. Diab Care 29 12 (2006) 2701-2707
32. Davis T.M., Bruce D.G., and Davis W.A. Prevalence and prognostic implications of the metabolic syndrome in community-based patients with type 1 diabetes: the Fremantle Diabetes Study. Diab Res Clin Pract 78 3 (2007) 412-417
33. McGill M., Molyneaux L., Twigg S.M., and Yue D.K. The metabolic syndrome in type 1 diabetes: does it exist and does it matter?. J Diab Complicat 22 1 (2008) 18-23
34. Reaven G.M. Banting Lecture 1988: role of insulin resistance in human disease. Diabetes 37 (1988) 1595-1607
35. Orchard T.J., Olson J.C., Erbey J.R., Williams K., Forrest K.Y.-Z., Smithline Kinder L., et al. Insulin resistance-related factors, but not glycemia, predict coronary artery disease in type 1 diabetes. Diab Care 26 (2003) 1374-1379
36. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
37. Cusi K., and De Fronzo R.A. Metformin: a review of its metabolic effects. Diab Rev 6 (1998) 132
38. Janssen M., Rillaerts E., and De Leeuw I. Effects of metformin on haemorheology, lipid parameters and insulin resistance in insulin-dependent diabetic patients (IDDM). Biomed Pharmacother 45 8 (1991) 363-367
39. Hamilton J., Cummings E., Zdravkovic V., Finegood D., and Daneman D. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. Diab Care 26 1 (2003) 138-143
40. Strowig S.M., and Raskin P. The effect of rosiglitazone on overweight subjects with type 1 diabetes. Diab Care 28 7 (2005) 1562-1567